Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

SWIFT-seq was able to successfully capture CTCs in 90% of patients with MGUS, SMM, and MM. | Image credit: luchschenF - stock.adobe.com
Novel Blood Test Could Transform Multiple Myeloma Diagnosis, Monitoring

August 23rd 2025

Investigators believe the SWIFT-seq system holds potential to replace more invasive bone marrow biopsies.

Whether KRd‐based quadruplets will redefine the frontline standard now hinges on proving they can deliver deeper, longer‐lasting remissions without compromising safety. | Image credit: Dzmitry - stock.adobe.com
Carfilzomib‐Based Quadruplets Challenge VRd as Frontline Multiple Myeloma Backbone

August 21st 2025

Myeloma cells | Image: ASH image bank
On the Path to Greater Precision in Treating Multiple Myeloma

August 18th 2025

The model has the potential to boost early detection of MM and contribute to a paradigm shift in the treatment of MM. | Image credit: shidlovski - stock.adobe.com
Model Based on EHR Parameters Can Predict 5-Year Multiple Myeloma Risk

August 13th 2025

Joseph Mikhael, MD | Image: T-GEN
How M-Power Is Building Trust to Raise Awareness of Multiple Myeloma in the Black Community

August 12th 2025

Experts Weigh in on Multiple Myeloma

Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.

AJMC Insights logo displayed on a blue abstract background with light and dark wave patterns.
Continuing Medical Education
View All
August 27th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 27th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
August 27th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer
August 27th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
August 27th 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

Binod Dhakal, MD, Medical College of Wisconsin, lead CARTITUDE-4 investigator
April 24th 2024

Dr Binod Dhakal Discusses Game-Changing Cilta-Cel Approval for RRMM

Maggie L. Shaw
Binod Dhakal, MD, associate professor, Medical College of Wisconsin, is lead investigator of the CARTITUDE-4 study, from which data were used by the FDA to approve ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least 1 prior line of therapy.
Janssen image | Image Credit: Sundry Protography - stock.adobe.com
April 23rd 2024

Talquetamab Cost-Effective Breakthrough for RRMM

Maggie L. Shaw
The FDA granted accelerated approval to talquetamab on August 9, 2023, as a treatment option for adult patients with relapsed/refractory multiple myeloma (RRMM) who have failed at least 4 prior lines of therapy.
Open book on multiple myeloma | Image Credit: FelipeCaparros - stock.adobe.com.
April 11th 2024

Study Urges Personalized Care to Boost Quality of Life in Patients With MM

Maggie L. Shaw
Treatment and management of multiple myeloma (MM) is continuously evolving, and in this analysis, investigators discuss ever-present issues and potential solutions to optimize care for this patient population.
FDA approval indication | Image Credit: Dzmitry - stock.adobe.com
April 6th 2024

FDA Approves Cilta-Cel for Earlier Treatment of RRMM

Maggie L. Shaw
Most recently, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend ciltacabtagene autoleucel (Carvykti; Johnson & Johnson) in patients who have received at least 1 line of treatment for relapsed/refractory multiple myeloma (RRMM).
FDA Approved
April 5th 2024

Ide-Cel Receives Approval for Earlier Treatment for Relapsed, Refractory Multiple Myeloma

Julia Bonavitacola
Idecabtagene vicleucel (ide-cel) was able to triple progression-free survival and reduce the risk of disease progression or death in a phase 3 trial.
Book of cases on multiple myeloma | Image Credit: FelipeCaparros - stock.adobe.com
March 27th 2024

Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma

Maggie L. Shaw
Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Multiple Myeloma Diagram | Image Credit: fancytapis - stock.adobe.com
March 21st 2024

Fracture Risk Lowest for Alendronate, Pamidronate Use During MM Treatment

Maggie L. Shaw
In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from facilitating jaw degradation and reducing vertebral fracture risk among patients being treated for multiple myeloma.
Imran Khan, MD, PhD, Johnson & Johnson
March 12th 2024

Dr Imran Khan Addresses Teclistamab’s Groundbreaking Impact and Ongoing Promise

Maggie L. Shaw
Teclistamab (Tecvayli, Johnson & Johnson), a first-in-class bispecific T-cell–engaging antibody, is approved to treat relapsed/refractory multiple myeloma in the US.
Imran Khan, MD, PhD, Johnson & Johnson
March 4th 2024

Dr Imran Khan Presents a Closer Look at Teclistamab’s Weight-Based Dosing and Patient-Centric Approach

Maggie L. Shaw
The FDA recently approved the supplemental biologics license application for teclistamab (Tecvayli; Johnson & Johnson) to treat relapsed/refractory multiple myeloma on a biweekly dosing schedule.
Imran Khan, MD, PhD, Johnson & Johnson
February 27th 2024

Dr Imran Khan Discusses Teclistamab’s Expanded Indication for RRMM

Maggie L. Shaw
Teclistamab (Tecvayli) was first approved for use in patients who have relapsed/refractory multiple myeloma (RRMM) in October 2022, making it a first-in-class bispecific antibody.
enFuse injector | Image: Enable Injections
February 27th 2024

On-Body Delivery System enFuse Saves Time, Improves QOL for Patients

Mary Caffrey
An on-body delivery system approved last fall for paroxysmal nocturnal hemoglobinuria (PNH) has seen rapid uptake and is now being studied for use with isatuximab.
Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma
February 23rd 2024

Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma

AJMC Staff
The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows a dosing frequency of 1.5 mg/kg every 2 weeks.
Multiple myeloma diagnosis | Image credit: ibreakstock - stock.adobe.com
February 15th 2024

Daratumumab-Based Regimen Potential Promising Bridging Therapy for RRMM

Maggie L. Shaw
The combination of daratumumab and immumodulatory therapy was evaluated among patients with relapsed/refractory multiple myeloma (RRMM) who have failed prior treatment with immunomodulatory agents, proteasome inhibitors, and daratumumab as monotherapy or in combination.
Doctor is holding diagnosis Multiple myeloma | Image credit: Vitalii Vodolazskyi - stock.adobe.com.jpeg
February 7th 2024

Disability Degree, Home Health Use May Signal Need for Patient Support in MM

Maggie L. Shaw
Clinical investigators evaluated the impact of home health services on disability status and receipt of treatment among adults 66 years and older with a new diagnosis of multiple myeloma (MM).
multiple myeloma, text on white paper near stethoscope on blue background | Image credit: Svetlana stock.adobe.com.jpeg
January 29th 2024

Best Practices That Target Selinexor Treatment Improve MM-Related Outcomes

Maggie L. Shaw
Patient survival and such treatment-related outcomes as time to treatment failure and treatment duration improved following implementation of a best practices program that focused on selinexor administration for multiple myeloma (MM), with implications for other anticancer medications.
Health Disparities Poster | image credit: Colored Lights - stock.adobe.com
January 26th 2024

Racial Disparities Persist in Multiple Myeloma Treatment

Kyle Munz
A claims-based study analyzing Medicare beneficiaries with multiple myeloma found that racial disparities still impact treatment in this patient population.
EBO logo
January 20th 2024

Overcoming Barriers to Care Equity in Multiple Myeloma

Rose McNulty
Holding hands with an elderly patient
January 19th 2024

Additional Analyses Needed to Optimize Treatment Efficacy, Sequencing in MM

Maggie L. Shaw
This literature review investigated outcomes related to relapsed/refractory multiple myeloma (MM) among patients 65 years and older.
Managing finances in health care | Image Credit: janews094 - stock.adobe.com
January 13th 2024

New Research Further Supports Use of Financial Navigators in Myeloma Care

Kristie L. Kahl
Patients with multiple myeloma are living longer; therefore, their lifelong treatment expenses can become burdensome.
Doctor with patient in medical office | Image Credit: sebra - stock.adobe.com
January 4th 2024

Understanding the Patient Experience With Belantamab Mafodotin for RRMM

Maggie L. Shaw
A qualitative interview study gauged patients’ experiences with belantamab mafodotin, which is used to treat relapsed/refractory multiple myeloma (RRMM) following failure on at least 4 prior therapies.
Alissa Visram, MD | Image credit: Ottawa Hospital Research Institute
December 27th 2023

Study Finds Huge Gap Between Clinical Trial Data and Real-World Outcomes in Multiple Myeloma

Mary Caffrey
Real-world patients were on average older and had more comorbidities than those in clinical trials, factors previously seen in comparisons between patients in clinical trials and real-world settings.
Highlights From EHA 2023
December 26th 2023

ICYMI: Highlights From EHA 2023

Rose McNulty
The most-read articles from the 2023 European Hematology Association (EHA) Annual Meeting covered the most up-to-date treatment strategies for hematological malignancies, racial disparities in treatment patterns for blood cancers, and updates on immunotherapy as a tool in hematologic oncology.
L. Andres Sirulnik, MD, PhD | Image credit: Regeneron
December 22nd 2023

LINKER-MM1: Updated Data Show 46% Complete Responses to Linvoseltamab at 11 Months in R/R Multiple Myeloma

Mary Caffrey
Regeneron officials say they are on track to file for FDA approval for the bispecific antibody by the end of 2023.
Multiple myeloma | Image credit: David Litman - stock.adobe.com
December 20th 2023

Older, Younger Patients With MM Show Similar Outcomes With Teclistamab

Rose McNulty
Real-world data presented at the 2023 American Society of Hematology Annual Meeting and Exposition showed similar toxicity profiles and outcomes among older and younger patients with multiple myeloma (MM) treated with teclistamab.
EBO
December 19th 2023

From CAR T’s “Wait List Mortality” to “Tethering” Bispecific Antibodies, Oncologists Navigate Time-Sensitive Sequencing in Multiple Myeloma

Ryan Flinn
Top 5 Multiple Myeloma Articles of 2023
December 19th 2023

Top 5 Most-Read Multiple Myeloma Articles of 2023

Rose McNulty
Our top multiple myeloma (MM) content this year included research suggesting many patients still face poor prognoses despite advances, a case study of unique MM presentation, and research presented at the 2022 American Society of Hematology Annual Meeting.
Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com
December 16th 2023

Talquetamab Dose Modifications May Lower AEs While Maintaining Efficacy in R/R Multiple Myeloma

Silas Inman
Dose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma.
Illustration of T cells - Sebastian - stock.adobe.com
December 15th 2023

Patients With Multiple Myeloma Lack Awareness of CAR T-Cell Therapy, Research Says

Giuliana Grossi
The results indicated that a substantial proportion of patients, particularly in rural, less educated, and elderly demographics, are insufficiently informed about novel MM treatments, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibody alternatives.
Cardiovascular system | Image credit: appledesign - stock.adobe.com
December 8th 2023

Real-World Data Show Poor Outcomes Among Patients With ACS and Blood Cancers

Sabrina Serani
A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Blood Cells | Image credit: Катерина Євтехова - stock.adobe.com
November 30th 2023

Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma

Rose McNulty
A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
<123456789
...
13>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo